All Stories

  1. Thromboembolic events in peripartum cardiomyopathy: results from the ESC EORP PPCM registry
  2. Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in‐hospital and long‐term outcomes – from the ESC‐HFA EORP Heart Failure Long‐Term Registry
  3. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
  4. Diminishing benefits of urban living for children and adolescents’ growth and development
  5. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  6. Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology
  7. Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026
  8. The overlapping burden of the three leading causes of disability and death in sub-Saharan African children
  9. Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study
  10. Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society o...
  11. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019
  12. Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry
  13. Cohort Profile: The ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
  14. Mapping development and health effects of cooking with solid fuels in low-income and middle-income countries, 2000–18: a geospatial modelling study
  15. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  16. Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit
  17. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry
  18. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  19. May Measurement Month 2019: analysis of blood pressure screening in Bishkek, Kyrgyzstan
  20. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
  21. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
  22. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe
  23. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020
  24. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the Global Burden of Disease Study 2019
  25. Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation ...
  26. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
  27. Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019
  28. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
  29. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC‐EHRA EURObservational research programme in atrial fibrillation general long‐term registry
  30. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
  31. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study
  32. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019
  33. Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis
  34. Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry
  35. Primary stroke prevention worldwide: translating evidence into action
  36. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry
  37. Contemporary Management of Severe Symptomatic Aortic Stenosis
  38. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
  39. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry
  40. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018
  41. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019
  42. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  43. Tracking development assistance for health and for COVID-19
  44. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
  45. Markers of cardiovascular risk and their reversibility with acute oxygen therapy in Kyrgyz highlanders with high altitude pulmonary hypertension
  46. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
  47. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology
  48. Measuring routine childhood vaccination coverage in 204 countries and territories
  49. Child Mortality Trends and Targets: GBD 2019 Findings
  50. Potential for optimizing management of obesity in the secondary prevention of coronary heart disease
  51. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
  52. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
  53. Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018
  54. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)
  55. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  56. The state of stroke services across the globe: Report of World Stroke Organization–World Health Organization surveys
  57. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  58. Pregnancy outcomes in women with a systemic right ventricle and transposition of the great arteries results from the ESC-EORP Registry of Pregnancy and Cardiac disease (ROPAC)
  59. Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality
  60. Burden of Ischemic Heart Disease in Central Asian Countries, 1990–2017
  61. The Heart Failure Association Atlas : Heart Failure Epidemiology and Management Statistics 2019
  62. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight
  63. Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease
  64. Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme
  65. Peripheral arterial disease and intermittent claudication in coronary heart disease patients
  66. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model
  67. Mapping routine measles vaccination in low- and middle-income countries
  68. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
  69. Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants
  70. Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: Findings from the ESC-EORP EUROASPIRE V survey
  71. Five insights from the Global Burden of Disease Study 2019
  72. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019
  73. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  74. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  75. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17
  76. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
  77. Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
  78. Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17
  79. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  80. May Measurement Month 2019
  81. Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  82. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017
  83. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  84. Repositioning of the global epicentre of non-optimal cholesterol
  85. Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017
  86. Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)
  87. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
  88. The Kyrgyz Society of Cardiology
  89. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
  90. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  91. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
  92. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3
  93. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC‐EORP Heart Failure Long‐Term Registry
  94. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries
  95. The Heart Failure Association Atlas: rationale, objectives, and methods
  96. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  97. Coronary patients and diabetes in Europe
  98. GBD 2016. Occupational Carcinogens Collaborators
  99. Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016
  100. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  101. ‘Medicine of the Silk Road’
  102. The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017
  103. Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
  104. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  105. Mapping child growth failure across low- and middle-income countries
  106. Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017
  107. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017
  108. The prevalence of major cardiovascular risk factors in rural population of the Chui region of Kyrgyzstan: results of an epidemiological study
  109. The Joint Scientific Symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC) in the frame of the International Symposium “Medicine of the Silk Road”
  110. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  111. Mapping disparities in education across low- and middle-income countries
  112. Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry
  113. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017
  114. Contemporary Presentation and Management of Valvular Heart Disease
  115. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
  116. Kyrgyz Society of Cardiology Annual Congress 2019
  117. THE ESC ACCA EAPCI EORP Acute Coronary Syndrome ST elevation myocardial infarction (ACS STEMI) REGISTRY
  118. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050
  119. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
  120. Rising rural body-mass index is the main driver of the global obesity epidemic in adults
  121. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  122. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  123. The frequency of familial hypercholesterolemia amongst patients in the outpatient clinic of the tertiary specialized cardiology center in Kyrgyzstan
  124. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry
  125. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016
  126. The Silk Road Symposium 2018
  127. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  128. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017
  129. OUP accepted manuscript
  130. A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC)
  131. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  132. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease ...
  133. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  134. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  135. Measuring progress of the health-related Sustainable Development Goals for 195 countries
  136. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  137. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  138. Association between the intima-media thickness of the extracranial carotid arteries and metabolic syndrome in ethnic Kyrgyzs
  139. The Role of the European Society of Cardiology in improving the quality of cardiac care at the level of national cardiac societies
  140. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
  141. Reduced Introgression of Sex Chromosome Markers in the Mexican Howler Monkey (Alouatta palliata × A. pigra) Hybrid Zone
  142. Alcohol use and attributable disease burden in 195
  143. Measuring performance_Healthcare Access_Quality Index for 195 countries and territories
  144. An Association of Cardiovascular Risk Factors with T1264G of CD 36 Gene Polymorphism in Kyrgyz Population
  145. Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015
  146. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40
  147. The Burden of Cardiovascular Diseases Among US States, 1990-2016
  148. The scientific and educational activity of the European Atherosclerosis Society (EAS) in Kyrgyzstan
  149. 2018 ESC Guidelines for the diagnosis and management of syncope
  150. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants
  151. The association of Val109Asp polymorphic marker of intelectin 1 gene with abdominal obesity in Kyrgyz population
  152. “Medicine of the Silk Road”
  153. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
  154. The Kyrgyzstan Cardiology Congress, 2017
  155. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry
  156. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016
  157. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
  158. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  159. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  160. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  161. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016
  162. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
  163. Health Effects of Overweight and Obesity in 195 Countries over 25 Years
  164. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015
  165. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
  166. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
  167. Association between sleep apnoea and pulmonary hypertension in Kyrgyz highlanders
  168. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
  169. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  170. Dexamethasone reduces pulmonary artery pressure in lowlanders with COPD travelling to 3200m. A randomized, placebo-controlled trial: TABLE 1
  171. Risk of malignant arrhythmia in highlanders with high altitude pulmonary hypertension during wakefulness and sleep
  172. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases
  173. Cerebral oxygenation in highlanders with and without high-altitude pulmonary hypertension
  174. Association Between T455C Polymorphism of Apolipoprotein C-III Gene, Insulin Resistance and Metabolic Syndrome Components
  175. Intravenous Contrast Material and Acute Kidney Injury: A Need for Caution
  176. AB1078 Diagnostic Value of Serological Markers in Rheumatoid Arthritis in Patients of Kyrgyz Republic
  177. CardioPulse ArticlesThe 2014 ESC Guidelines on the Diagnosis and Management of Hypertrophic Cardiomyopathy have been publishedThe ‘Ten Commandments’ of the ESC Hypertrophic Cardiomyopathy GuidelinesEuroPCR 2014, Hypertension and Heart Failure Track tak...
  178. 2014 ESC/ESA Guidelines on non-cardiac surgery
  179. CardioPulse Articles
  180. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management
  181. Sleep Apnea and Ectopic Fat Deposition
  182. Rhabdomyolysis
  183. Prevalence of health risk behaviors and their associated factors among university students in Kyrgyzstan
  184. Lipids and leptin level in natives of Kyrgyzstan
  185. The association of leptin with dyslipidemia, arterial hypertension and obesity in Kyrgyz (Central Asian nation) population
  186. Systemic Tentacles of Chronic Obstructive Pulmonary Disease: Do We Need to Account for Renal Damage?
  187. Obstructive sleep apnoea, gout and cardiovascular risk: A worth studying association
  188. Types of Sleep Apnea in Patients With Heart Failure
  189. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: Is There a Place for Obstructive Sleep Apnea?
  190. Sleep disordered breathing and cardiovascular disease: Another brick in the wall
  191. High-sensitivity cardiac troponin in patients with stable chronic obstructive pulmonary disease: looking beyond the lungs
  192. Obstructive Sleep Apnea and Sodium Intake
  193. Chronic Obstructive Pulmonary Disease and Vascular Risk: Should We Account for Diabetes Mellitus and Renal Disease?
  194. Obstructive Sleep Apnea and Autoimmune Disease: A Two-Way Process
  195. Comment on: Obstructive sleep apnoea in relation to rheumatic disease
  196. Obstructive sleep apnea: Looking at the whole picture
  197. Frequency of C825T G protein β3 subunit gene polymorphism and its association with obesity in the Kyrgyz population
  198. Prevalence of obstructive sleep apnea in Asian adults: a systematic review of the literature
  199. Response to Independent Association Between Obstructive Sleep Apnea and Noncalcified Coronary Plaque Demonstrated by Noninvasive Coronary Computed Tomography Angiography
  200. Obstructive sleep apnea and dyslipidemia: importance of the liver axis
  201. Remembering: Academician Mirsaid Mirrakhimov (1927-2008)
  202. Cut off values for abdominal obesity as a criterion of metabolic syndrome in an ethnic Kyrgyz population (Central Asian region)
  203. Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease
  204. An association between TRP64ARG polymorphism of the B3 adrenoreceptor gene and some metabolic disturbances
  205. Rheumatologic services in Central Asian countries: current state of development of rheumatology in Central Asia
  206. The effects of 12-month lovastatin therapy on carotid atherosclerosis in patients with hyperlipidemia
  207. Evaluation of the economic efficiency of educational programs for patients with coronary heart disease and dyslipidemia
  208. Silent ischemia and prognosis after acute myocardial infarction